Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTERIFIED ESTROGENS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTERIFIED ESTROGENS.
DIETHYLSTILBESTROL vs ESTERIFIED ESTROGENS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Estrogen replacement therapy; binds to estrogen receptors (ERα and ERβ), activating transcription of estrogen-responsive genes, promoting proliferation of endometrial and breast epithelium, and exerting effects on bone, cardiovascular, and central nervous systems.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
1.25 mg orally once daily for 21 days, followed by a 7-day drug-free period per cycle. Adjust based on response.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 10-24 hours, reflecting the prolonged activity of conjugated metabolites and enterohepatic cycling. Steady-state is achieved within 3-5 days.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Esterified estrogens are metabolized in the liver and undergo enterohepatic recirculation. Approximately 60-80% of the dose is excreted in the urine (as glucuronide and sulfate conjugates), with the remaining 20-40% excreted in feces via bile.
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."